CVR number 33162790
Industry 75.0000 Veterinary activities

LINDEVANG DYREKLINIK ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  6.0% 10.3% 6.5% 5.0% 4.3%  
Credit score (0-100)  39 22 36 43 48  
Credit rating  BBB BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  1,308 1,447 1,546 1,776 1,848  
EBITDA  328 -117 125 410 365  
EBIT  328 -122 113 372 268  
Pre-tax profit (PTP)  327.4 -127.4 104.3 333.9 228.7  
Net earnings  255.4 -123.9 104.4 265.8 174.5  
Pre-tax profit without non-rec. items  327 -127 104 334 229  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  14.6 9.8 187 589 551  
Shareholders equity total  580 456 560 726 800  
Interest-bearing liabilities  0.0 0.0 0.0 380 313  
Balance sheet total (assets)  1,046 842 966 1,609 1,607  
Net Debt  -818 -666 -435 -347 -515  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,308 1,447 1,546 1,776 1,848  
Gross profit growth  -26.0% 10.6% 6.9% 14.9% 4.1%  
Employees  2 3 3 4 4  
Employee growth %  0.0% 50.0% 0.0% 33.3% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,046 842 966 1,609 1,607  
Balance sheet change%  71.0% -19.5% 14.8% 66.5% -0.1%  
Added value  328.3 -117.0 124.8 384.0 365.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -5 -10 166 365 -136  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 -1.0 1.0 2.0 3.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  25.1% -8.4% 7.3% 21.0% 14.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  39.6% -12.9% 12.5% 28.9% 16.6%  
ROI %  72.6% -23.5% 22.3% 43.8% 23.3%  
ROE %  56.5% -23.9% 20.5% 41.3% 22.9%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  55.4% 54.2% 58.0% 45.1% 49.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -249.1% 569.1% -348.7% -84.6% -141.0%  
Gearing %  0.0% 0.0% 0.0% 52.4% 39.1%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 20.2% 11.2%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.9 1.8 1.4 1.5 1.7  
Current Ratio  2.2 2.2 1.8 1.8 1.9  
Cash and cash equivalent  817.7 665.7 435.1 727.0 828.2  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  544.7 444.9 307.2 413.9 459.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  164 -39 42 96 91  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  164 -39 42 102 91  
EBIT / employee  164 -41 38 93 67  
Net earnings / employee  128 -41 35 66 44